Emiliano Cocco

ORCID

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 10

Top Venues

British journal of cancer

Nature communications

JCO precision oncology

Cancers

This page only lists publications with an associated author ORCID identifier.

Publications

Paola Roa, Valentina Foglizzo, Guilherme Harada, Matteo Repetto, Amanda Kulick, Elisa de Stanchina, Michelle de Marchena, Supipi Auwardt, Shaza Sayed Ahmed, Nicole Virginia Bremer, Soo-Ryum Yang, Yangbo Feng, Chao Zhou, Norman Kong, Ruixia Liang, Haipeng Xu, Bin Zhang, Alberto Bardelli, Eneda Toska, Andrea Ventura, Alexander E Drilon, Emiliano Cocco
Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents. British journal of cancer (2024)
Paola Roa, Valentina Foglizzo, Guilherme Harada, Matteo Repetto, Amanda Kulick, Elisa de Stanchina, Michelle de Marchena, Supipi Auwardt, Shaza Sayed Ahmed, Nicole Virginia Bremer, Soo-Ryum Yang, Yangbo Feng, Chao Zhou, Norman Kong, Ruixia Liang, Haipeng Xu, Bin Zhang, Alberto Bardelli, Eneda Toska, Andrea Ventura, Alexander E Drilon, Emiliano Cocco
Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents. British journal of cancer 131 (3) (2024)
Paola Roa, Valentina Foglizzo, Guilherme Harada, Matteo Repetto, Amanda Kulick, Elisa de Stanchina, Michelle de Marchena, Supipi Auwardt, Shaza Sayed Ahmed, Nicole Virginia Bremer, Soo-Ryum Yang, Yangbo Feng, Chao Zhou, Norman Kong, Ruixia Liang, Haipeng Xu, Bin Zhang, Alberto Bardelli, Eneda Toska, Andrea Ventura, Alexander E Drilon, Emiliano Cocco
Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents. British journal of cancer 131 (3) (2024)
Paola Roa, Valentina Foglizzo, Guilherme Harada, Matteo Repetto, Amanda Kulick, Elisa de Stanchina, Michelle de Marchena, Supipi Auwardt, Shaza Sayed Ahmed, Nicole Virginia Bremer, Soo-Ryum Yang, Yangbo Feng, Chao Zhou, Norman Kong, Ruixia Liang, Haipeng Xu, Bin Zhang, Alberto Bardelli, Eneda Toska, Andrea Ventura, Alexander E Drilon, Emiliano Cocco
Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents. British journal of cancer (2024)
Paola Roa, Valentina Foglizzo, Guilherme Harada, Matteo Repetto, Amanda Kulick, Elisa de Stanchina, Michelle de Marchena, Supipi Auwardt, Shaza Sayed Ahmed, Nicole Virginia Bremer, Soo-Ryum Yang, Yangbo Feng, Chao Zhou, Norman Kong, Ruixia Liang, Haipeng Xu, Bin Zhang, Alberto Bardelli, Eneda Toska, Andrea Ventura, Alexander E Drilon, Emiliano Cocco
Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents. British journal of cancer 131 (3) (2024)
Monica F Chen, Soo-Ryum Yang, Jinru Shia, Jeffrey Girshman, Sippy Punn, Clare J Wilhem, Mark G Kris, Emiliano Cocco, Alexander E Drilon, Nitya Raj
Response to Repotrectinib After Development of NTRK Resistance Mutations on First- and Second-Generation TRK Inhibitors. JCO precision oncology 7 (2023)
Ezra Y Rosen, Helen H Won, Youyun Zheng, Emiliano Cocco, Duygu Selcuklu, Yixiao Gong, Noah D Friedman, Ino De Bruijn, Selcuk Onur Sumer, Craig M Bielski, Casey Savin, Caitlin Bourque, Christina Falcon, Nikeysha Clarke, Xiaohong Jing, Fanli Meng, Catherine Zimel, Sophie Shifman, Srushti Kittane, Fan Wu, Marc Ladanyi, Kevin Ebata, Jennifer Kherani, Barbara J Brandhuber, James A Fagin, Eric J Sherman, Natasha Rekhtman, Michael F Berger, Maurizio Scaltriti, David M Hyman, Barry S Taylor, Alexander E Drilon
Author Correction: The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers. Nature communications 13 (1) (2022)
Ezra Y Rosen, Helen H Won, Youyun Zheng, Emiliano Cocco, Duygu Selcuklu, Yixiao Gong, Noah D Friedman, Ino De Bruijn, Selcuk Onur Sumer, Craig M Bielski, Casey Savin, Caitlin Bourque, Christina Falcon, Nikeysha Clarke, Xiaohong Jing, Fanli Meng, Catherine Zimel, Sophie Shifman, Srushti Kittane, Fan Wu, Marc Ladanyi, Kevin Ebata, Jennifer Kherani, Barbara J Brandhuber, James A Fagin, Eric J Sherman, Natasha Rekhtman, Michael F Berger, Maurizio Scaltriti, David M Hyman, Barry S Taylor, Alexander E Drilon
The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers. Nature communications 13 (1) (2022)
Erik Ladewig, Flavia Michelini, Komal Jhaveri, Hatice Ulku Osmanbeyoglu, Javier Carmona, Lauren Fairchild, Adler G Zuniga, Amaia Arruabarrena-Aristorena, Emiliano Cocco, Ryan Blawski, Srushti Kittane, Yuhan Zhang, Mirna Sallaku, Laura Baldino, Vasilis Hristidis, Sarat Chandarlapaty, Omar Abdel-Wahab, Christina S Leslie, Maurizio Scaltriti, Eneda Toska
The Oncogenic PI3K-Induced Transcriptomic Landscape Reveals Key Functions in Splicing and Gene Expression Regulation. Cancer research 82 (12) (2022)
Valentina Foglizzo, Emiliano Cocco, Serena Marchiò
Advanced Cellular Models for Preclinical Drug Testing: From 2D Cultures to Organ-on-a-Chip Technology. Cancers 14 (15) (2022)

Emiliano Cocco.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Emiliano Cocco